Lanoxin and Xigris drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lanoxin (digoxin) and Xigris (drotrecogin alfa (activated)). Common drug interactions include activated partial thromboplastin time prolonged among females and activated partial thromboplastin time prolonged among males.

The phase IV clinical study analyzes what interactions people have when they take Lanoxin and Xigris. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Lanoxin?

Lanoxin has active ingredients of digoxin. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 21,852 Lanoxin users. Check the latest studies of Lanoxin.

What is Xigris?

Xigris has active ingredients of drotrecogin alfa (activated). eHealthMe is studying from 3,542 Xigris users. Check the latest studies of Xigris.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 03, 2026

11 people who take Lanoxin and Xigris together, and have interactions are studied.

Lanoxin and Xigris drug interactions.

What are the common drug interactions of Lanoxin and Xigris, by gender? *:

female:

  1. Activated partial thromboplastin time prolonged
  2. Haematocrit decreased
  3. International normalised ratio increased
  4. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  5. Prothrombin time shortened
  6. Thrombocytopenia (decrease of platelets in blood)

male:

  1. Activated partial thromboplastin time prolonged
  2. Haematocrit decreased
  3. Respiratory failure (inadequate gas exchange by the respiratory system)
  4. Ventricular dysfunction (heart dysfunction)
  5. Waterhouse-friderichsen syndrome (adrenal gland failure due to bleeding into the adrenal glands, caused by severe bacterial infection)
  6. Activated partial thromboplastin time shortened
  7. Blood fibrinogen increased
  8. Blood urea increased
  9. Faecal occult blood positive
  10. International normalised ratio decreased

What are the common drug interactions of Lanoxin and Xigris, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Cardiac failure
  2. Cerebral infarction (less blood supply to brain resulting tissue damage)
  3. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  4. Ejection fraction decreased (systolic heart failure)
  5. Intraventricular haemorrhage (intraventricular bleeding)
  6. Ventricular dysfunction (heart dysfunction)
  7. Waterhouse-friderichsen syndrome (adrenal gland failure due to bleeding into the adrenal glands, caused by severe bacterial infection)
  8. Activated partial thromboplastin time prolonged
  9. Activated partial thromboplastin time shortened
  10. Haematocrit decreased

20-29:

n/a

30-39:

n/a

40-49:

  1. Activated partial thromboplastin time prolonged
  2. Blood urea increased
  3. Faecal occult blood positive
  4. Haematocrit decreased
  5. Haemoglobin decreased
  6. Platelet count decreased
  7. White blood cell count increased
  8. Bacterial infection
  9. Blood creatine increased
  10. Blood creatinine increased

50-59:

n/a

60+:

  1. Activated partial thromboplastin time prolonged
  2. Haematocrit decreased
  3. Thrombocytopenia (decrease of platelets in blood)
  4. International normalised ratio increased
  5. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  6. Platelet count decreased
  7. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  8. Prothrombin time shortened
  9. Renal failure acute (rapid kidney dysfunction)
  10. Respiratory failure (inadequate gas exchange by the respiratory system)

What are the existing conditions these people have? *

  1. Sepsis (a severe blood infection that can lead to organ failure and death): 3 people, 27.27%
  2. Meningitis Meningococcal (a bacterial infection of the membranes covering the brain and spinal cord (meninges)): 2 people, 18.18%
  3. Septic Shock (shock due to blood infection): 1 person, 9.09%
  4. Psychotic Disorder: 1 person, 9.09%
  5. Meningococcal Infection (a bacterial infection caused by meningococcal bacteria): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lanoxin and Xigris?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lanoxin and Xigris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lanoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Xigris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lanoxin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xigris and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on digoxin and drotrecogin alfa (activated) (the active ingredients of Lanoxin and Xigris, respectively), and Lanoxin and Xigris (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: